SCHEMBL10127965

SCHEMBL10127965

Nc1ccc2c(c1)OCCN2CCCN1CCOCC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 1/20 0.45
SLC6A4 P31645 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.41
MAPT P10636 3/20 0.41
GAA P10253 2/20 0.41
NOS3 P29474 1/20 0.41
NOS1 P29475 1/20 0.41
NOS2 P35228 1/20 0.41
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 4/20 0.41
TP53 P04637 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
KDM1A O60341 3/20 0.39
SIGMAR1 Q99720 2/20 0.38
POLB P06746 1/20 0.38
KEAP1 Q14145 1/20 0.38
ALDH3A1 P30838 1/20 0.37
HTT P42858 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17525476 0.93 NOS3 (0.46) HTR1ASLC6A4SMN1; SMN2MAPTGAA
SCHEMBL17525491 0.92 KDM1A (0.45) HTR1ASLC6A4SMN1; SMN2MAPTGAA
SCHEMBL17525510 0.91 NOS3 (0.47) HTR1ASLC6A4MAPTGAANOS3
SCHEMBL17525475 0.90 NOS3 (0.46) HTR1ASLC6A4MAPTGAANOS3
SCHEMBL282767 0.88 HTR1A (0.49) HTR1ASLC6A4MAPTGAANOS3
SCHEMBL17525509 0.87 HTR1A (0.46) HTR1ASLC6A4SMN1; SMN2MAPTGAA
SCHEMBL17525490 0.86 KDM1A (0.43) SMN1; SMN2MAPTGAANOS3NOS1
SCHEMBL17690579 0.85 HTR1A (0.44) HTR1ASLC6A4SMN1; SMN2NOS3NOS1
SCHEMBL17859576 0.85 HTR1A (0.44) HTR1ASLC6A4MAPTGAANOS3
SCHEMBL2074785 0.85 NOS3 (0.54) HTR1ASLC6A4SMN1; SMN2MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180141922-A1 BENZOXAZINE DERIVATIVES AND USE IN HAIR DYEING L'OREAL (FR) 2018-05-24 US disclosed
US-20180141922-A1 BENZOXAZINE DERIVATIVES AND USE IN HAIR DYEING L'OREAL (FR) 2018-05-24 US disclosed
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
WO-2016020490-A1 BENZOXAZINE DERIVATIVES AND USE IN HAIR DYEING L'OREAL (FR) 2016-02-11 WO disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141922-A1 BENZOXAZINE DERIVATIVES AND USE IN HAIR DYEING XDH, KRT18, CYC1 HTR1A 802/4885SLC6A4 2280/4885SMN1; SMN2 4081/4885
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 HTR1A 3884/4885SLC6A4 4001/4885SMN1; SMN2 4467/4885
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 HTR1A 3884/4885SLC6A4 4001/4885SMN1; SMN2 4467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.